Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
Authors:
- 25 January 2010
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (10) , 1502-1507
Abstract
Haematopoietic SCT (HSCT) offers the only potentially curative option in chronic myelomonocytic leukaemia (CMML). In this study, we report on single-centre results of 18 patients with CMML who have undergone allogeneic HSCT. The median age of patients was 54 years. Seven patients had AML, which had transformed from CMML. Overall, 11 patients received stem cells from an unrelated donor. A total of 15 patients received a T-cell-depleted fludarabine/BU-based reduced-intensity conditioning HSCT. The actuarial 3-year OS, non-relapse mortality (NRM) and relapse incidence for the cohort was 31±11%, 31±14% and 47±13%, respectively. Patients with favourable cytogenetics had a 3-year disease-free survival of 65±17%, whereas none of the seven patients with intermediate or poor risk cytogenetics survived beyond 2 years (PP5% blasts at the time of transplantation (that is, 20.0±13%). Recipient age, type of conditioning regimen or stem cell dose did not have a significant impact on overall outcomes. Our data support existing evidence that allogeneic HSCT is a feasible therapeutic option for CMML, with the ability to attain long-term remission among patient subgroups.Keywords
This publication has 9 references indexed in Scilit:
- Outcome of allo-SCT for chronic myelomonocytic leukemiaBone Marrow Transplantation, 2008
- Delayed attainment of full donor chimaerism following alemtuzumab‐based reduced‐intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomesBritish Journal of Haematology, 2007
- Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromesBritish Journal of Haematology, 2006
- Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemiaBone Marrow Transplantation, 2006
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood, 2004
- Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative DisordersMayo Clinic Proceedings, 2003
- Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)British Journal of Haematology, 2002
- Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patientsBlood, 2002
- International Scoring System for Evaluating Prognosis in Myelodysplastic SyndromesBlood, 1997